Literature DB >> 10726965

Haemodynamic responses to a ring-deleted analogue of atrial natriuretic peptide in rats with cirrhosis.

R Moreau1, K A Tazi, H Komeichi, E Pussard, D Lebrec.   

Abstract

AIMS: In cirrhosis, the effects of selective activation of atrial natriuretic peptide (ANP) R2-receptors on haemodynamics, endogenous ANP (ANP1-28) and sodium excretion are unknown. The aim of the present study was to examine the effects of selective activation of ANP-R2 receptors by ANP4-23 (a ring-deleted analogue of endogenous ANP) on haemodynamics, plasma ANP1-28 concentrations and urinary sodium excretion in conscious cirrhotic and normal rats.
METHODS: Haemodynamics and sodium excretion were measured prior to and following administration of ANP4 23. Plasma ANP1-28 concentrations were also measured.
RESULTS: In cirrhotic rats, ANP4-23 significantly decreased portal pressure and tributary blood flow by 15% and 25% respectively but significantly increased portal territory vascular resistance by 30%. Systemic and renal haemodynamics were not altered by ANP4-23. In normal rats, ANP4-23 did not significantly change splanchnic, renal and systemic haemodynamics. In both groups of rats, ANP4-23 increased plasma ANP1-28 concentrations but did not change sodium excretion.
CONCLUSIONS: ANP4-23 administration induced splanchnic vasoconstriction in cirrhotic but not in normal rats. ANP4-23-elicited vasoconstriction caused a portal hypotensive effect in cirrhotic rats. Finally, in both groups, ANP4-23 caused an increase in plasma ANP1-28 concentrations but did not increase sodium excretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726965     DOI: 10.1034/j.1600-0676.2000.020001088.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  1 in total

1.  Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.

Authors:  Shao-Jung Hsu; Hui-Chun Huang; Chiao-Lin Chuang; Ching-Chih Chang; Ming-Chih Hou; Fa-Yauh Lee; Shou-Dong Lee
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.